Anthem Biosciences (NSE:ANTHEM) EBIT: ₹6,433 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ANTHEM Anthem Biosciences Ltd NSE:ANTHEM
34 GF Score
Price ₹747.65
! 2 Warning Signs
View Full Analysis

What is Anthem Biosciences EBIT?

Anthem Biosciences NSE:ANTHEM -0.93% 34 EBIT is ₹6,433 Mil as of Mar. 2026. GuruFocus rates NSE:ANTHEM with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Anthem Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹2,798 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹6,433 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anthem Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 was 26.24%. Anthem Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 68.76%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Anthem Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 1.56%.

Anthem Biosciences  (NSE:ANTHEM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anthem Biosciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=9104.96 * ( 1 - 31.72% )/( (0 + 23692.69)/ 1 )
=6216.866688/23692.69
=26.24 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=34292.9 - 1215.24 - ( 9384.97 - max(0, 3257.14 - 18031.45+9384.97))
=23692.69

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Anthem Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=11192.64/( ( (0 + max(0, 0)) + (10664.52 + max(5613.26, 0)) )/ 1 )
=11192.64/( ( 0 + 16277.78 )/ 1 )
=11192.64/16277.78
=68.76 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5905.88 + 1245.16 + 1466.29) - (1215.24 + 0 + 1788.83)
=5613.26

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Anthem Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=6432.76/411119.631
=1.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthem Biosciences EBIT Related Terms

Anthem Biosciences EBIT Historical Data

* Premium members only.

The historical data trend for Anthem Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anthem Biosciences EBIT Chart

Anthem Biosciences Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
5,577.01 5,054.98 4,865.94 6,668.84 8,307.81

Anthem Biosciences Quarterly Data
Mar22 Mar23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only 1,636.00 1,788.32 2,326.34 1,308.26 2,798.16

NSE:ANTHEM vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Anthem Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anthem Biosciences EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anthem Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anthem Biosciences's EV-to-EBIT falls into.


NSE:ANTHEM
34GF Score
Anthem Biosciences Ltd NSE:ANTHEM
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anthem Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹6,433 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹6,433 Mil mean?
Anthem Biosciences (NSE:ANTHEM) has a EBIT of ₹6,433 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anthem Biosciences.
Is Anthem Biosciences' EBIT too high?
Anthem Biosciences' current EBIT is ₹6,433 Mil. Overall, Anthem Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' EBIT compare to VRTX and REGN?
Anthem Biosciences' EBIT of ₹6,433 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Anthem Biosciences. Anthem Biosciences's current EBIT is ₹6,433 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current EBIT of ₹6,433 Mil. The current EBIT is ₹6,433 Mil. Anthem Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current EBIT is ₹6,433 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anthem Biosciences Business Description

Other Exchanges 544449:India
Address No. 49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase 1, Bommasandra, Bangalore, KA, IND, 560 099
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
34GF Score

Get the complete analysis for NSE:ANTHEM

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹747.65
Price